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S U M M A R Y
From 2005 to 2009, at Detroit Medical Center, the prevalence of Providencia stuartii increased from 0.52
to 0.91/1000 patient-days (p < 0.001). The use of colistin also increased (p < 0.001) during the study
period. The increase in the prevalence of P. stuartii was associated with an increased use of colistin
(p < 0.001). Facilities that frequently use colistin and tigecycline should closely monitor the prevalence
of P. stuartii along with other Proteeae, since these organisms are intrinsically resistant to colistin and
tigecycline.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
A 54-year-old female patient was admitted to the Detroit
Medical Center (DMC) in November 2010. Her past medical
history was signiﬁcant for multiple sclerosis, cerebrovascular
disease, diabetes mellitus, and multiple recurrences of urinary
tract infections (UTIs) related to her chronic/permanent urinary
catheter. The patient presented to the hospital in septic shock,
and was later found to be bacteremic with both Proteus mirabilis
and Providencia stuartii. A urine culture grew P. stuartii. Three
months earlier, the patient had experienced an episode of UTI
caused by carbapenem-resistant Klebsiella pneumoniae, which
was treated with a 10-day course of tigecycline; this resulted in
complete resolution of the infection. Due to this prior infectious
episode, the patient was initially treated empirically with
broad-spectrum agents including colistin, cefepime, and vanco-
mycin. Once Proteus and P. stuartii were identiﬁed in the blood
culture, the antibiotic regimen was changed to ceftriaxone
monotherapy. The patient was successfully treated and
discharged. Due to this case and others like it, we became
concerned that the recent increase in usage of tigecycline and* Corresponding author. Tel.: +1 313 745 1714; fax: +1 313 993 0302.
E-mail address: kayokohayakawa@gmail.com (K. Hayakawa).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.05.1029colistin at our institutions might have created a selection
pressure favoring the isolation of P. stuartii from clinical
cultures.
P. stuartii is typically a urinary pathogen isolated from patients
with long-term indwelling urinary catheters residing in nursing
homes, but can also be a cause of bacteremia and invasive
infections.1 P. stuartii has intrinsic resistance determinants and is
commonly resistant to aminopenicillins and early generation
cephalosporins. Furthermore, plasmid-mediated resistance mech-
anisms such as extended-spectrum beta-lactamases (ESBLs) and
metallo-beta-lactamases (MBLs) have also been recovered from P.
stuartii strains causing clinical infection.2
Tigecycline and colistin are two drugs that are used to treat
multidrug-resistant organisms. Often, they are the only two agents
available with in vitro activity against resistant pathogens such as
Acinetobacter baumannii and carbapenem-resistant Enterobacter-
iaceae (CRE). Due to the increasing frequency of both A. baumannii
and CRE at our institution,3,4 both tigecycline and colistin have
been used with increasing frequency. Both of these drugs have no
clinically relevant activity against P. stuartii.5,6
The objectives of this study were to explore the trend in
frequency of isolation of P. stuartii from clinical cultures and the
trend in colistin and tigecycline utilization at DMC. In addition, we
aimed to correlate the prevalence of P. stuartii with the usage of
colistin and tigecycline.ses. Published by Elsevier Ltd. All rights reserved.
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The DMC consists of eight hospitals and over 2200 inpatient
beds. A central microbiology laboratory processes over 500 000
cultures annually, and antibiograms are reported biannually in
accordance with the Clinical and Laboratory Standards Institute
(CLSI) criteria.7 A broth microdilution MicroScan1 automated
system was used for the identiﬁcation of bacteria and for antibiotic
susceptibility testing. The medical records of all patients with P.
stuartii clinical isolates obtained from January 1, 2005 to December
31, 2009 were retrospectively reviewed. If a patient had multiple
episodes of P. stuartii during the study period, all episodes were
included. Deﬁned daily doses (DDD) of tigecycline and colistin use
for the study period were obtained from pharmacy records.
SAS (version 9.2; SAS Institute, Cary, NC, USA) was used for all
statistical analyses. Poisson logistic regression was used for
analyzing trends over the study years and the association between
trends in the prevalence of P. stuartii and the consumption in DDDs
of tigecycline and colistin.
3. Results
During the 5-year study period, the prevalence of P. stuartii at
the DMC signiﬁcantly increased from 168 isolations (prevalence of
0.52/1000 patient-days) in 2005 to 288 isolations (0.91/1000
patient-days) in 2009 (p for trend < 0.001) (Table 1). Tigecycline
and colistin were ﬁrst used at DMC in 2006, and since then the
consumption in DDDs for both drugs has increased, reaching 1106
tigecycline DDDs and 4196 colistin DDDs in 2009. Colistin DDDs
increased signiﬁcantly over the study period (p for trend < 0.001),
however the increase in tigecycline DDDs was not statistically
signiﬁcant. On bivariate analysis, the increment in P. stuartii
isolations was signiﬁcantly associated with the increased use of
colistin (p < 0.001). No association was found between the
increased prevalence of P. stuartii and the use of tigecycline.
Susceptibility of P. stuartii to various antibiotics did not change
signiﬁcantly during the study period (Table 1).
4. Discussion
The increased frequency of isolation of A. baumannii and CRE at
DMC led to an increased utilization of tigecycline and colistin
during the study period.3,4 Concomitantly, the prevalence of P.
stuartii also increased at our institution during the study period.
Because tigecycline and colistin are not active against P. stuartii, we
hypothesized that, due to selective antimicrobial pressure, there
would be an association between increased usage of tigecycline
and/or colistin and increased recovery of P. stuartii. Selective
antimicrobial pressure is difﬁcult to measure in clinical settings.
Infection control practices and global obscure trends can affect
results pertaining to recovery of clinical organisms.
The limitation of this study is that we included all the clinical
isolates of P. stuartii during the study period, and the differentia-
tion of infection and colonization was not made. No statistical
signiﬁcance was observed pertaining to the trend of usage of
tigecycline over the study period, nor its correlation to P. stuartii
isolation. A longer study period might have been able to
demonstrate such a correlation.
Facilities that frequently use colistin and tigecycline should
closely monitor the prevalence of P. stuartii along with other
Proteeae, since these organisms are intrinsically resistant to colistin
and tigecycline. Such monitoring is particularly important, because
carbapenemases are now being isolated at an increasing frequency
among Proteeae including among P. stuartii isolates.2,8–10 Thus, in
addition to monitoring the frequency of isolation of P. stuartii, it
might be beneﬁcial to screen for carbapenemase production in these
K. Hayakawa et al. / International Journal of Infectious Diseases 16 (2012) e646–e648e648isolates. The judicious use of antibiotics and the strong implemen-
tation of stewardship programs that promote discontinuation and
de-escalation of antibiotics such as colistin and tigecycline when
they are no longer clinically needed, combined with strict infection
control measures to reduce the prevalence of A. baumannii and CRE,
are all strategies that can be used to reduce the emergence and
spread of P. stuartii.
Conﬂict of interest: All authors report no conﬂicts of interest
relevant to this article.
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